Logo image of MTSR

METSERA INC (MTSR) Stock Fundamental Analysis

NASDAQ:MTSR - US59267L1070 - Common Stock

36.29 USD
+0.63 (+1.77%)
Last: 9/4/2025, 8:23:42 PM
36.24 USD
-0.05 (-0.14%)
After Hours: 9/4/2025, 8:23:42 PM
Fundamental Rating

2

Taking everything into account, MTSR scores 2 out of 10 in our fundamental rating. MTSR was compared to 542 industry peers in the Biotechnology industry. MTSR has a great financial health rating, but its profitability evaluates not so good. MTSR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

MTSR had negative earnings in the past year.
MTSR Yearly Net Income VS EBIT VS OCF VS FCFMTSR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

With a Return On Assets value of -55.41%, MTSR perfoms like the industry average, outperforming 46.49% of the companies in the same industry.
MTSR's Return On Equity of -78.90% is in line compared to the rest of the industry. MTSR outperforms 53.14% of its industry peers.
Industry RankSector Rank
ROA -55.41%
ROE -78.9%
ROIC N/A
ROA(3y)-26.59%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MTSR Yearly ROA, ROE, ROICMTSR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 50 -50

1.3 Margins

MTSR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MTSR Yearly Profit, Operating, Gross MarginsMTSR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, MTSR has about the same amount of shares outstanding.
The debt/assets ratio for MTSR is higher compared to a year ago.
MTSR Yearly Shares OutstandingMTSR Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 20M 40M 60M 80M 100M
MTSR Yearly Total Debt VS Total AssetsMTSR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

MTSR has an Altman-Z score of 9.80. This indicates that MTSR is financially healthy and has little risk of bankruptcy at the moment.
MTSR has a better Altman-Z score (9.80) than 85.61% of its industry peers.
There is no outstanding debt for MTSR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.8
ROIC/WACCN/A
WACCN/A
MTSR Yearly LT Debt VS Equity VS FCFMTSR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 5.26 indicates that MTSR has no problem at all paying its short term obligations.
With a Current ratio value of 5.26, MTSR perfoms like the industry average, outperforming 57.38% of the companies in the same industry.
A Quick Ratio of 5.26 indicates that MTSR has no problem at all paying its short term obligations.
MTSR has a Quick ratio (5.26) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 5.26
Quick Ratio 5.26
MTSR Yearly Current Assets VS Current LiabilitesMTSR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M

0

3. Growth

3.1 Past

The earnings per share for MTSR have decreased strongly by -342.97% in the last year.
EPS 1Y (TTM)-342.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, MTSR will show a very negative growth in Earnings Per Share. The EPS will decrease by -12.18% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-3.2%
EPS Next 2Y-6.43%
EPS Next 3Y-12.18%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MTSR Yearly EPS VS EstimatesMTSR Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -1 -2 -3 -4

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MTSR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MTSR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MTSR Price Earnings VS Forward Price EarningsMTSR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MTSR Per share dataMTSR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A cheap valuation may be justified as MTSR's earnings are expected to decrease with -12.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.43%
EPS Next 3Y-12.18%

0

5. Dividend

5.1 Amount

No dividends for MTSR!.
Industry RankSector Rank
Dividend Yield N/A

METSERA INC

NASDAQ:MTSR (9/4/2025, 8:23:42 PM)

After market: 36.24 -0.05 (-0.14%)

36.29

+0.63 (+1.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-28 2025-07-28/amc
Earnings (Next)N/A N/A
Inst Owners78.06%
Inst Owner Change10.43%
Ins Owners0.91%
Ins Owner Change0%
Market Cap3.81B
Analysts86
Price Target58.48 (61.15%)
Short Float %11.17%
Short Ratio8.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.61%
Min EPS beat(2)-18.8%
Max EPS beat(2)1.59%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.24%
PT rev (3m)21.99%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-2.56%
EPS NY rev (3m)2.44%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.49
P/tB 10.88
EV/EBITDA N/A
EPS(TTM)-3.71
EYN/A
EPS(NY)-3.7
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS4.28
TBVpS3.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -55.41%
ROE -78.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.59%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.26
Quick Ratio 5.26
Altman-Z 9.8
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-342.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-3.2%
EPS Next 2Y-6.43%
EPS Next 3Y-12.18%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-571.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-133.45%
EBIT Next 3Y-58.08%
EBIT Next 5YN/A
FCF growth 1Y-182.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-182.65%
OCF growth 3YN/A
OCF growth 5YN/A